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Abstract The present study discusses evaluation of
pullulan-functionalized doxorubicin nanoparticles for asia-
loglycoprotein receptor-mediated uptake in the Hep G2 cell
line. Doxorubicin hydrochloride (DOX) nanoparticles using
polymers of different hydrophobic character, polyethylene
sebacate (hydrophobic) and poly (lactic-co-glycolic acid)
(intermediate hydrophobicity) with high entrapment effi-
ciency and particle size were prepared by modified nano-
precipitation, using Gantrez AN 119 as complexing agent.
Nanoparticles of Gantrez AN 119 were also prepared to
represent a hydrophilic polymer. Cell uptake of DOX
nanoparticles was found to be comparable to DOX solution
irrespective of DOX concentration, nanoparticles size, and
pullulan concentration. Furthermore, uptake of nanopar-
ticles functionalized with or without pullulan prepared with
polymers of different hydrophobic character revealed
comparable uptake. Comparable uptake of DOX solution
and DOX nanoparticles functionalized with or without
pullulan suggest extracellular release of DOX as the
mechanism of uptake from the nanoparticles. In vivo
evaluation in hepatic cancer model is therefore essential to
confirm the role of pullulan as asialoglycoprotein receptors
ligand.
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1 Introduction
Doxorubicin hydrochloride (DOX) is a drug of choice in
the treatment of hepatic cancer. Insufficient concentration at
the tumor site due to P-glycoprotein efflux coupled with
cardiotoxicity, nephrotoxicity, myelosuppression, and top-
oisomerase II resistance are serious limitations of current
DOX therapy (Patil et al. 2008). Efficient treatment of
hepatic cancer may be facilitated through hepatocyte-
specific delivery of DOX. Asialoglycoprotein receptors
(ASGPR) are predominantly present in large numbers on
the sinusoidal cell membrane of hepatocytes and internalize
sugars such as galactose or lactose and glycoproteins with
terminal galactose or N-acetylgalactosamine by endocytosis
(Wu et al. 2002). Targeting to ASGPR using nanocarriers
represents an attractive strategy for hepatocyte-specific
delivery of DOX for the treatment of hepatic cancer.
Various ligands for ASGPR including its natural
ligand asialo-feutin (Arangoa et al. 2003) or galactosy-
lated or lactosylated polymers (Kawakami et al. 1998;
2000), glucoside (Maitani et al. 2001), glycolipids
(Sliedregt et al. 1999) when functionalized on to nano-
carriers resulted in enhanced targeting to hepatocytes.
Pullulan (PUL), a water-soluble polysaccharide polymer
comprising three α-1, 4-linked glucose molecules that are
repeatedly polymerized at α-1, 6-linkages on terminals
glucose, was reported to be accumulated in the liver at
significantly higher amounts than other water-soluble
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polymers (Yamaoka et al. 1993; 1995). Chemical conju-
gation of interferon (Suginoshita et al. 2002) and DNA
(Hosseinkhani et al. 2002) with pullulan enabled enhanced
targeting to the liver. The binding of iodine-labeled
pullulan to isolated parenchymal cells was inhibited by
known ligands of ASGPR suggesting ASGPR-mediated
uptake. Further, the internalization of pullulan via
ASGPR-mediated endocytosis has been confirmed by
fluorescence microscopy (Kaneo et al. 2001).
Recently we have reported the design of pullulan-
functionalized polyethylene sebacate (PES)-DOX nano-
particles for improved hepatic targeting. Comparative
biodistribution study in rats using 99mTc-labeled formu-
lations revealed high blood concentration and long
circulating nature of nanoparticles, and hence the possi-
bility of improved targeting to hepatocytes (Guhagarkar et
al. 2010).
The aim of the present study is to evaluate in vitro, the
ASGPR-mediated uptake of pullulan-functionalized DOX
nanoparticles in Hep G2 cell lines, with the specific
objective of understanding the role of nanoparticle size
and composition on cell uptake. The polymers selected for
design of DOX nanoparticles included hydrophobic poly-
mer PES, polymer of intermediate hydrophobicity poly
(lactic-co-glycolic acid) (PLGA) and hydrophilic polymer
Gantrez AN 119 (copolymer of methyl vinyl ether and
maleic anhydride).
2 Materials and methods
2.1 Materials
Doxorubicin hydrochloride was obtained from Hovid Sdn
Bhd (Malaysia) as gift sample. Gantrez AN 119 ISP
(Molecular weight 200000) was obtained as a gift sample
from Anshul Agencies (Mumbai, India). PES was synthe-
sized in our laboratory (molecular weight; 9,625). PLGA
50:50 (PDLG 5010; inherent viscosity midpoint of 1 dl/g)
was purchased from PURASORB®. Tween 80, magnesium
acetate, tetrahydrofuran (THF), acetone, and sodium lauryl
sulfate were purchased from S.D. Fine Chemicals (Mum-
bai, India). Acetonitrile HPLC grade was provided as gift
2.2 Synthesis of PES
PES was synthesized in our laboratory by a two-step
reaction involving initial esterification between ethylene
glycol and sebacic acid to form a diester, dihydroxy
ethylene sebacate oligomer. This was followed by
condensation reaction between two ester dimmers to
form PES. PES was characterized by gel permeation
chromatography, FTIR, 1H-NMR, differential scanning
calorimetry, and X-ray diffraction. Toxicity studies
including genotoxicity and mutagenicity have confirmed
safety of PES for biomedical and pharmaceutical appli-
cations (More et al. 2009).
2.3 Preparation of nanoparticles
PES-DOX nanoparticle (NP) was prepared by modified
nanoprecipitation. PES (20 mg) and Gantrez AN 119
(Gantrez; 5 mg) were dissolved in 10 ml of THF and
acetone (1:1). DOX (10 mg) and tween 80 (10% v/v) were
dissolved in water (25 ml). The organic phase was added
drop-wise to the aqueous phase under magnetic stirring
followed by addition of aqueous solution of magnesium
acetate tetrahydrate (1 ml of 0.5% w/v) as a stabilizing
agent for Gantrez. The resulting dispersion was stirred for a
period of 4 h to ensure complete evaporation of the organic
solvents. This was followed by addition of pullulan (nano-
particles: pullulan ratio 1:1/1:2) to prepared pullulan-
functionalized nanoparticles. PLGA-DOX NP was prepared
as above by simple replacement of PES with PLGA.
Gantrez-DOX NP was prepared as above without addition
of PLGA or PES in the organic phase.
PES-DOX NP dispersion was centrifuged (Z36HK
Hermle, Germany) at 20,000 rpm for 30 min. The
supernatant was analyzed for entrapment efficiency and
the pellet obtained was dispersed in distilled water/distilled
water containing pullulan (nanoparticles: pullulan ratio 1:1/
1:2) by probe sonication (DP120, Dakshin, Mumbai, India)
for a period of 10 min with a 15 s on/off cycle to obtain
nanoparticles of larger size.
2.4 Evaluation of nanoparticles
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sample by Azeocryst Organics Pvt Ltd (Mumbai. India).
Pullulan (molecular weight, 200 kD) from Hayashibara,
Japan was supplied as gift sample by Gangwal Chemicals
Pvt. Ltd. (Mumbai, India). Eagle's Minimum Essential
Medium (EMEM), fetal bovine serum, EDTA, and trypsin
was purchased from HIMEDIA®. Gentamycin injection IP
(40 mg/ml) was obtained from local suppliers. Distilled
water was used throughout the experiments. All other
chemicals and reagents were either spectroscopic or
analytical grade.
2.4.1 Entrapment efficiency and drug loading
The supernatant obtained after centrifugation was suitably
diluted and analyzed for free DOX by UV spectrophotom-
etry (Shimadzu, Japan) at 478 nm. The percentage
entrapment efficiency was calculated as follows:
% Entrapment efficiency
¼ ½ DOXð Þtotal  DOXð Þsupernatant= DOXð Þtotal  100
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Drug loading was calculated using the following formula
%Drug loading ¼ ½ amount of DOX entrapped in nanoparticlesð Þ=
amount of DOX added þ amount of drug and polymers addedð Þ  100
2.4.2 Particle size
Particle size was determined by photon correlation spec-
troscopy using the N4 plus submicron particle size analyzer
(Beckman Coulter, USA) at 25°C. All measurements were
taken by scattering light at 90°. The nanoparticulate
dispersion was diluted with water (filtered through
0.22 μm membrane filter) to obtain final counts per second
(intensity), 5×104 to 1×106 and the particle size was
recorded.
2.4.3 Zeta potential
The Zeta potential of nanoparticles was determined using
Zeta sizer Nano ZS (Malvern Instruments Ltd., Malvern,
UK). The nanoparticulate dispersion was diluted and the
zeta potential determined.
2.5 Cell uptake studies
Human hepatoma cells, HepG2, were used as the model
cell line for evaluation of uptake of DOX nanoparticles.
Cells were obtained from the National Institute of Cell
Sciences, Pune, India. The cells were grown on EMEM
containing 1 mM sodium pyruvate supplemented with 10%
fetal bovine serum, and 40 mg/ml gentamycin, at 37°C.
Cells were trypsinized on reaching 90% confluence.
Hep G2 cells were seeded in 24-well plates at
densities of 3–4×105cells/well and allowed to adhere by
incubating for a period of 24 h at 37°C. The medium was
discarded and replaced with DOX solution and DOX
nanoparticles. The plate was then incubated at 37°C for a
period of 1 h. At the end of 1 h, supernatant was collected
and the cells lysed in the wells using 0.5% w/v sodium
lauryl sulfate solution (200 μl). Trypsin-EDTA solution
(100 μl) was added to facilitate cell detachment. The DOX
content in the cell lysate was determined by high-
performance liquid chromatography.
The liquid chromatographic system Jasco LC900, con-
sisting of a Jasco PU-980 Intelligent HPLC pump (Jasco,
Japan) coupled with a Jasco UV-975 Intelligent UV/VIS
detector and a Rheodyne injector (model 7725) fitted with a
20-μl sample loop, was employed for the study. Data
integration was done using Borwin Chromatography soft-
ware version 1.21. Chromatography was performed on a
Spherisorb® 250×4.6 mm HPLC cartridge prepacked with
Spherisorb® 5 μm ODS2 (Waters, USA). The mobile phase
comprised of acetonitrile (40%) and water containing 0.1%
w/v triethylamine with pH adjusted to 3 with ortho-
phosphoric acid (60%). The mobile phase was degassed
by sonication prior to use. Chromatography was performed
at room temperature under isocratic conditions at a flow
rate of 1.0 ml/min with UV detection at a λmax of 254 nm.
Cell uptake of PES-DOX NP and PES-DOX-PUL was
evaluated at two different concentrations of DOX viz. 10
and 50 μg/ml and nanoparticles/pullulan ratio 1:1 and 1:2
while nanoparticle size was maintained at ∼200 nm.
Comparative evaluation of nanoparticles of the three
polymers PES, PLGA, and Gantrez functionalized with
pullulan (nanoparticles: pullulan 1:1) was also carried out at
DOX concentration of 10 μg/ml while nanoparticle size
was maintained at ∼125 nm. DOX nanoparticles without
pullulan and DOX solution served as controls.
2.6 Statistical analysis
All data in tables and figures are expressed as mean ±
standard deviation and mean ± standard error, respectively.
Statistical analysis was performed using the one-way
ANOVA with Dunnet test and Student's t tests. p<0.05
was the criterion for statistical significance.
3 Results
The entrapment efficiency, drug loading, particle size, and
zeta potential of nanoparticles are reported in Table 1. PES-
DOX NP prepared by modified nanoprecipitation technique
using Gantrez as a complexing agent revealed high
entrapment efficiency and high drug loading. Entrapment
efficiency and drug loading decreased with increased
hydrophobicity of polymers and was in the order Gantrez-
DOX-NP>PLGA-DOX NP>PES-DOX NP. Functionaliza-
tion with pullulan did not influence the particle size and
zeta potential of nanoparticles.
Cellular uptake of DOX from PES NP (∼200 nm) is
depicted in Fig. 1. Cell uptake of PES-DOX NP and PES-
DOX-PUL was comparable to DOX solution (p>0.05).
Further, increase in pullulan concentration did not enhance
the cellular uptake of nanoparticles. Although uptake of
PES-DOX-PUL at 50 μg/ml was significantly higher (p<
0.05, t test) than PES-DOX-PUL at 10 μg/ml it was
comparable to DOX solution (50 μg/ml). Decreasing particle
size of PES NP to ∼125 nm revealed no change (p>0.05) in
uptake. Comparative evaluation of nanoparticles of the three
polymers (∼125 nm) is depicted in Fig. 2. Surprisingly, the
uptake with all the three polymers was comparable (p>0.05)
despite differences in their hydrophobic character. Moreover,
functionalization with pullulan did not enhance cell uptake
even at the higher concentration of pullulan.
4 Discussion
Development of multidrug resistance and toxicity associat-
ed with higher doses, poses significant challenges in the
treatment of hepatic cancer using DOX. However design of
nanoparticulate carriers of DOX can address these issues by
overcoming P-glycoprotein-mediated efflux thereby in-
creasing intracellular drug concentration and drug cytotox-
icity (Barraud et al. 2005). Previous studies have reported
increased antitumor efficacy of DOX-PIHCA nanoparticles
when evaluated in hepatic metastases model in mice. DOX-
PIHCA nanoparticles were found to accumulate in the
Kupffer cells of the liver which served as drug reservoir
inducing release of DOX to the neighboring metastatic cells
(Chiannilkulchai et al. 1990). However, this can result in
toxicity to the Kupffer cells and other macrophages when
conventional nanocarriers are used (Brigger et al. 2002). A
significant dose of DOX in the hepatocytes, the site of
action for the drug can be achieved by targeting to the
ASGPR, abundantly present on hepatocytes. Moreover,
ASGPR are reported to be overexpressed in hepatic cancer
(Trouet and Jolles, 1984). DOX coupled to lactosaminated
human serum albumin has been extensively studied as
hepatotropic carrier to improve the chemotherapeutic index
of DOX in the treatment of hepatic cancer (Stefano et al.
2006; Fiume et al. 2008). Poly[N-(2-hydroxypropyl)meth-
acrylamide] copolymer bearing DOX and galactosamine,
known as PK2 was found to enhance hepatic targeting
when evaluated in primary hepatocellular tumors (Julyan et
al. 1999; Seymour et al. 2002).
In the present study, pullulan-functionalized nanopar-
ticles of DOX with high entrapment efficiency and high
drug loading were designed for targeting to ASGPR. The
high entrapment efficiency is attributed to ionic complex-
ation between Gantrez and DOX and the modified nano-
precipitation method followed for the preparation of
nanoparticles (Guhagarkar et al. 2010). The same was
observed with PLGA-DOX NP. Negative zeta potential
values can be attributed to the free carboxyl groups of
Gantrez.
ASGPR is reported to be highly expressed on the surface
of several human hepatoma cell lines such as Hep G2.
Though most of the studies indicate enhanced uptake of
small size nanoparticles, there appear to be conflicting
reports regarding particle size and uptake by hepatocytes.
While an upper particle size limit of 80 nm has been
proposed by some researchers for high hepatocellular
uptake (Rensen et al. 2001), efficient uptake of liposomes
of size 227 nm by hepatocytes have been demonstrated by
others (Maitani et al. 2001). Recently, Huang et al. (2008)
Fig. 1 Effect of particle size and DOX concentration on uptake of
PES-DOX NP in Hep G2 cell line (mean ± SE, n=3)
Fig. 2 Effect of polymer type on uptake of DOX nanoparticles in Hep
G2 cell line (mean ± SE, n=3)
Table 1 Entrapment efficiency, particle size, and zeta potential of nanoparticles (mean ± SD, n=3)
Nanoparticles Entrapment efficiency (%) Drug loading (%) Particle size (nm) Zeta potential (mV)
PES-DOX NP 75.92±2.4 21.6±0.62 210.3±2.3 −22.1±2.4
PES-DOX PUL 215.5±11.8 −21.9±0.5
PES-DOX NP 75.92±2.4 21.6±0.62 125.5±3 −19.9±1.65
PES-DOX PUL 128.4±2.8 −20.33±0.80
PLGA-DOX NP 81.09±0.14 23.16±0.06 129.7±0.9 −21.7±0.87
PLGA-DOX PUL 124.4±1.07 −23.4±1.64
Gantrez-DOX NP 87.90±0.24 58.60±0.18 133.6±1.7 −20.6±1.68
Gantrez-DOX PUL 130.5±3.3 −21.2±2.42
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reported greater association of galactosylated superpara-
magnetic iron oxide nanoparticles of 278-nm size to Hep
G2 cells. Zauner et al. (2001) observed internalization of
only few particles of polystyrene microsphere of 93 and
220 nm in Hepa 1-6 and Hep G2 cell line. In the present
study, no significant difference (p>0.05) in the uptake was
observed irrespective of size. Further functionalization with
pullulan revealed no specific enhancement on the cell
uptake.
Influence of surface hydrophobicity on cellular uptake is
well documented. Cell attachment experiments revealed
that interactions between Hep G2 cells and polymeric films
increased with increase in hydrophobicity (Hu et al. 2007).
On the hand decreased cellular uptake due to presence of
residual poly(vinyl) alcohol on nanoparticle surface has
also been reported (Sahoo et al. 2002). Pullulan-
functionalized nanoparticles of three polymers of different
hydrophobic character, revealed no significant difference in
uptake by Hep G2 cells. Anchoring of pullulan on to the
nanoparticles surface was however confirmed by lower
hemolytic potential and long circulating nature of pullulan-
coated DOX nanoparticles (Guhagarkar et al. 2010). Our
data corroborates with an earlier report on DOX liposomes
prepared using sterylglucosamine as ASGPR ligand which
did not show enhanced cell uptake in Hep G2 cell line,
nonetheless higher accumulation of DOX liposomes in liver
was observed in vivo in mouse and rat liver cancer model
(Shimizu et al. 1998; Maitani et al. 2001).
Affinity of ligand to ASGPR is strongly influenced by
ligand type and density and spacing of the ligand. For
instance, binding of N-acetylgalactosamine sugars to
ASGPR is more effective than galactose. Clustering of
glycosides was reported to enhance the affinity for ASGPR
and found to be in order tetraantennary>triantennary>>
biantennary>>monoantennary galactosides (Connolly et al.
1982). Higher ASGPR recognition of liposomes containing
glycolipids with tris-galactoside was reported by Sliedregt
et al. (1999). Moreover, appropriate spacing of sugar
residues (20>>10>>4 Å) is essential for optimum receptor
recognition (Biessen et al. 1995; Lee et al. 1983).
Degree of galactosylation of ligand also affected the
cellular uptake. Managit et al. (2005) found that uptake of
galactosylated lipid emulsion was dependent on concentra-
tion of galactosylated cholesterol derivatives used in the
preparation of emulsion. They found that at least 4 mol% of
galactosylated cholesterol derivatives was required for
recognition by receptor and 6 mol% resulted in extensive
ASGPR-mediated uptake in Hep G2 cell lines. Similar
observations were reported by Ogawara et al. (1998) on
hepatic uptake of galactosylated BSA derivatives in isolated
perfused rat liver, and by Han et al. (1999) on uptake of
methotrexate-carrying BSA conjugated with a greater
number of galactose moieties. Hashida et al. (1997)
evaluated hepatic targeting of galactosylated macromole-
cules including galactosylated proteins, polysaccharides
(dextran and amylase), and poly-amino acids. While good
correlation was observed between hepatic uptake clearance
and galactose density for galactosylated protein, such
correlation was not observed with galactosylated polysac-
charides and poly-amino acid. The linear structures of
polysaccharides and poly-amino acids could decrease the
apparent densities of galactose residues suggesting that
polysaccharides and poly-amino acids require more number
of galactose residues to be recognized by the ASGPR.
Chemically, pullulan is a linear polysaccharide and
consists of three α-1, 4-linked glucose molecules that are
repeatedly polymerized at α-1, 6-linkages on terminal
glucose. Suboptimal configuration of the glucose units
could have precluded extensive interaction of the glucose
units with the ASGPR. As reported with dextran and
amylase higher concentration of pullulan may be required
to enhance the cellular uptake by Hep G2 cells via ASGPR
due to its linear configuration.
Recently, Xu et al. (2010) evaluated the mechanism for
cellular uptake of PLGA nanoparticles and reported that
nanoparticles are not taken up by cells and deliver the drug
to the cells by extracellular release and/or direct drug
transfer to the contacting cells thus resulting in lower
cellular concentration with nanoparticles. Comparable
uptake of DOX solution and DOX nanoparticles with and
without pullulan, suggests extracellular release of DOX as
the mechanism of uptake from the nanoparticles in our
study. It appears therefore that in vitro evaluation in Hep
G2 cell lines may not be the best method to evaluate
ASGPR-mediated uptake of polysaccharide-based ligands
(Hashida et al. 1997)
Poor cellular uptake can also be related to negative
surface charge of nanoparticles. In general, positively
charged and neutral nanoparticles exhibit enhanced cellular
uptake compared to negatively charged particles (Lorenz et
al. 2006; Hu et al. 2007). Negative zeta potential of the
DOX nanoparticles could have resulted in repulsion
between particles and Hep G2 cells resulting in poor
cellular uptake.
5 Conclusion
The in vitro cell uptake studies in Hep G2 cell line could
not elucidate the role of pullulan as ASGPR ligand,
however in vivo studies in hepatic cancer model are
essential to confirm the role of pullulan as ASGPR
targeting agent.
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